Patents by Inventor Ulrich Demuth

Ulrich Demuth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VIRTUAL FUNCTIONAL MODULES FOR MEASURING DEVICES AND EQUIPMENT COMPONENTS
    Publication number: 20170315693
    Abstract: A system for detecting, analyzing and manipulating devices, wherein a virtual graphics component displays an operating state of the device and is integrated in a moving image of the device as a complete image, and wherein the complete image is updated at regular time intervals.
    Type: Application
    Filed: April 28, 2017
    Publication date: November 2, 2017
    Applicant: WIKA Alexander Wiegand SE & Co. KG
    Inventors: Ulrich DEMUTH, Thomas ROTHENBACH, Paul HANESCH
  • Uses of antibodies directed against amyloid-?
    Patent number: 9676843
    Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: June 13, 2017
    Assignee: PROBIODRUG AG
    Inventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Kathrin Gnoth, Anita Reisenauer-Schaupp, Jens-Ulrich Rahfeld, Sonja Kampfer
  • Diagnostic antibody assay
    Patent number: 9657089
    Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: May 23, 2017
    Assignee: PROBIODRUG AG
    Inventors: Martin Kleinschmidt, Stephan Schilling, Jens-Ulrich Rahfeld, Kristin Ebermann, Hans-Ulrich Demuth
  • Inhibitors
    Patent number: 9650362
    Abstract: The invention relates to novel pyrrolidine derivatives of formula (I): wherein R1, R2 and R3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: May 16, 2017
    Assignee: PROBIODRUG AG
    Inventors: Ulrich Heiser, Daniel Ramsbeck, Robert Sommer, Antje Meyer, Torsten Hoffmann, Livia Boehme, Hans-Ulrich Demuth
  • GLUTAMINYL CYCLASE AS A DIAGNOSTIC/PROGNOSTIC INDICATOR FOR NEURODEGENERATIVE DISEASES
    Publication number: 20170097365
    Abstract: A method for predicting, diagnosing and prognosticating a neurodegenerative disease, such as Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and neurodegeneration in Down's syndrome (NDS) using glutaminyl cyclase (QC) as a diagnostic/prognostic indicator. The use of antibodies binding to QC and kits for performing said diagnostic method are also provided.
    Type: Application
    Filed: December 14, 2016
    Publication date: April 6, 2017
    Inventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Jens-Ulrich Rahfeld, Astrid Kehlen, Monique Haegele
  • Radiolabelled glutaminyl cyclase (QC) inhibitors and uses of same
    Patent number: 9610368
    Abstract: Radiolabeled glutaminylcyclase (QC) inhibitors as imaging agents, in particular, but not exclusively, as medical imaging agents for the detection of neurological disorders; and pharmaceutical compositions, methods and kits for detecting neurological disorders, using the radiolabeled inhibitors.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: April 4, 2017
    Assignee: PROBIODRUG AG
    Inventors: Ulrich Heiser, Daniel Ramsbeck, Hans-Ulrich Demuth
  • Peptides that bind to amino-truncated amyloid-beta-peptide and use of said peptides
    Patent number: 9611296
    Abstract: Peptides that bind to amino-terminal truncated pEA?3-42, the free glutamic acid residue of which lies in position 3 or 11 in the form of cyclized pyroglutamate. Four oligopeptides were identified using mirror image phage display technology.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: April 4, 2017
    Assignee: Forschungszentrum Juelich GmbH
    Inventors: Dieter Willbold, Susanne Aileen Funke, Yeliz Cinar, Dirk Bartnik, Hans-Ulrich Demuth, Martin Kleinschmidt, Hans-Henning Ludwig
  • Use of Dipeptidyl Peptidase IV Effectors for Normalizing the Blood Glucose Level in Mammals
    Publication number: 20170007582
    Abstract: The present invention comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to lower elevated post-prandial and basal blood glucose levels in mammalian organisms. The invention further comprises the use of activity-reducing effectors of dipeptidyl peptidase (DP IV) and DP IV-analogous enzyme activity in the blood of a mammal to increase the half-life of incretins in vivo.
    Type: Application
    Filed: February 12, 2016
    Publication date: January 12, 2017
    Inventors: Hans-Ulrich Demuth, Fred Rosche, Joem Schmidt, Robert P. Pauly, Christopher H.S. McIntosh, Ray A. Pederson
  • Inhibitors
    Patent number: 9512115
    Abstract: The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein R1, R2, R3, R4 and R5 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: December 6, 2016
    Assignee: PROBIODRUG AG
    Inventors: Ulrich Heiser, Mirko Buchholz, Robert Sommer, Antje Meyer, Hans-Ulrich Demuth
  • Mouse carrying a knock-out mutation of the Qpct-gene
    Patent number: 9462793
    Abstract: The present invention provides a knock-out non-human animal, in particular a mouse carrying a Qpct knock-out mutation. The present invention additionally provides the respective cells and cell lines and methods and compositions for evaluating agents that affect Qpct, for use in compositions for the treatment of Qpct-related diseases.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: October 11, 2016
    Assignee: PROBIODRUG AG
    Inventors: Stephan Schilling, Torsten Hoffmann, Hans-Ulrich Demuth
  • Service device for air-conditioning systems
    Patent number: 9448140
    Abstract: A service or maintenance device is provided by which the maintenance work to be done on air-conditioning systems is made easier. An internal measuring system for the evaluation and display of measured data may have a display control means configured to optionally show measured values in a dynamic analog scale type in parallel to a numerical value, and to allow a comparison with a set memory marking.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: September 20, 2016
    Assignee: REFCO Manufacturing Ltd.
    Inventors: Manfred Ulrich, Ulrich Demuth
  • Mouse models carrying a knock-out mutation of the QPCTL-gene
    Patent number: 9277737
    Abstract: A knock-out non-human animal, in particular a mouse, carrying a QPCTL knock-out mutation. Additionally, respective cells and cell lines and methods and compositions for evaluating agents that affect QPCTL, for use in compositions for the treatment of QPCTL-related diseases are disclosed.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: March 8, 2016
    Assignee: PROBIODRUG AG
    Inventors: Hans-Ulrich Demuth, Anett Stephan, Birgit Koch, Holger Cynis, Stephan Schilling, Reinhard Sedlmeier, Sigrid Graubner
  • DIAGNOSTIC ANTIBODY ASSAY
    Publication number: 20160053001
    Abstract: Novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
    Type: Application
    Filed: September 3, 2015
    Publication date: February 25, 2016
    Inventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Kathrin Gans, Anita Reisenauer-Schaupp, Jens-Ulrich Rahfeld, Sonja Kampfer
  • NOVEL INHIBITORS
    Publication number: 20160039795
    Abstract: The invention relates to novel pyrrolidine derivatives of formula (I): wherein R1, R2 and R3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
    Type: Application
    Filed: September 23, 2015
    Publication date: February 11, 2016
    Inventors: Ulrich Heiser, Daniel Ramsbeck, Robert Sommer, Antje Meyer, Torsten Hoffmann, Livia Boehme, Hans-Ulrich Demuth
  • NOVEL INHIBITORS
    Publication number: 20160031869
    Abstract: The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein R1, R2, R3, R4 and R5 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: Ulrich Heiser, Mirko Buchholz, Robert Sommer, Antje Meyer, Hans-Ulrich Demuth
  • ANTIBODIES DIRECTED AGAINST PYROGLUTAMATE MONOCYTE CHEMOATTRACTANT PROTEIN-1 (MCP-1 N1PE)
    Publication number: 20150361167
    Abstract: Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE).
    Type: Application
    Filed: August 31, 2015
    Publication date: December 17, 2015
    Inventors: Holger Cynis, Hans-Ulrich Demuth, Jens-Ulrich Rahfeld, Stephan Schilling, Kathrin Gans, Sonja Kampfer
  • Inhibitors of glutaminyl cyclase
    Patent number: 9181233
    Abstract: The invention relates to novel heterocyclic derivatives as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
    Type: Grant
    Filed: March 3, 2011
    Date of Patent: November 10, 2015
    Assignee: PROBIODRUG AG
    Inventors: Ulrich Heiser, Daniel Ramsbeck, Torsten Hoffmann, Livia Boehme, Hans-Ulrich Demuth
  • Inhibitors
    Patent number: 9173885
    Abstract: The invention relates to novel pyrrolidine derivatives of formula (I): wherein R1, R2 and R3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: November 3, 2015
    Assignee: PROBIODRUG AG
    Inventors: Ulrich Heiser, Daniel Ramsbeck, Robert Sommer, Antje Meyer, Torsten Hoffmann, Livia Boehme, Hans-Ulrich Demuth
  • Antibodies directed against pyroglutamate monocyte chemoattractant protein-1 (MCP-1 N1pE)
    Patent number: 9157918
    Abstract: Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE).
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: October 13, 2015
    Assignee: PROBIODRUG AG
    Inventors: Holger Cynis, Hans-Ulrich Demuth, Jens-Ulrich Rahfeld, Stephan Schilling, Kathrin Gans, Sonja Kampfer
  • Diagnostic antibody assay
    Patent number: 9156907
    Abstract: Diagnostic assays for the diagnosis of amyloidosis, in particular, Alzheimer's disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: October 13, 2015
    Assignee: PROBIODRUG AG
    Inventors: Hans-Ulrich Demuth, Stephan Schilling, Martin Kleinschmidt, Kathrin Gans, Anita Reisenauer-Schaupp, Jens-Ulrich Rahfeld, Sonja Kampfer